Private company

Icosavax, Inc.

American biological products company, incorporated in Delaware1

In its 2023 annual report the company says: “We are a biopharmaceutical company leveraging our innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases. We are developing these candidates for older adults, a patient population with high unmet need. Our lead vaccine candidate IVX-A12 is a bivalent candidate, or a mixture of two different VLP candidates.”44 It is headquartered in Seattle, Washington.1

Last updated Oct 20, 2026.

Overview

  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersSeattle, Washington1
  • Incorporated inDE2
  • Business address1930 Boren Ave., Suite 1000, Seattle, Wa 981012
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-16333.0%Operating margin3
-15766.0%Net margin3
-92.5%Revenue growth, 20223
-42.1%Return on equity3
-$72.8MFree cash flow3

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Research and development100¢$65.4M

Out of $582.0K in revenue.3 The company lost money this year.

Financial statements

Revenue43$582.0K in 2022−64% since 2020
0$2.0M$4.0M$6.0M$8.0M2020: $1.6M$1.6M20202021: $7.8M$7.8M2021+383%2022: $582.0K$582.0K2022−93%
Operating income43-$95.1M in 2022+408% since 2020
-$100.0M-$75.0M-$50.0M-$25.0M02020: -$18.7M-$18.7M20202021: -$65.9M-$65.9M2021+252%2022: -$95.1M-$95.1M2022+44%
Net income43-$91.8M in 2022+387% since 2020
-$100.0M-$75.0M-$50.0M-$25.0M02020: -$18.9M-$18.9M20202021: -$67.0M-$67.0M2021+255%2022: -$91.8M-$91.8M2022+37%
Fiscal year2019202020212022
Revenue$1.6M4$7.8M3$582.0K3
Research and development$17.7M4$38.8M3$65.4M3
Operating expenses$73.7M3$95.6M3
Operating income-$18.7M4-$65.9M3-$95.1M3
Interest$417.0K4$263.0K3
Net income-$18.9M4-$67.0M3-$91.8M3
Earnings per share-$3.733-$2.313
Earnings per share (diluted)-$3.733-$2.313
Shares (weighted, basic)18.0M shares339.7M shares3
Shares (weighted, diluted)18.0M shares339.7M shares3

Compare Icosavax, Inc. with another company

Corporate structure

Icosavax, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Icosavax, Inc.

  • Qiming U.S. Healthcare GP II, LLC Filed SC 13D/A on Icosavax, Inc., latest Feb 21, 2024 (2 filings since Feb 28, 2022)
  • RA CAPITAL MANAGEMENT, L.P. Filed SC 13D/A on Icosavax, Inc., latest Feb 21, 2024 (2 filings since May 30, 2023)
  • CITADEL ADVISORS LLC Filed SC 13G/A on Icosavax, Inc., latest Feb 14, 2024 (2 filings since Jun 5, 2023)
  • Pentwater Capital Management LP Filed SC 13G on Icosavax, Inc., latest Feb 14, 2024
  • T. Rowe Price Investment Management, Inc. Filed SC 13G on Icosavax, Inc., latest Feb 14, 2024 (2 filings since Jan 10, 2023)
  • PLATINUM INVESTMENT MANAGEMENT LTD Filed SC 13G on Icosavax, Inc., latest Feb 12, 2024 (2 filings since Feb 9, 2023)
  • FMR LLC Filed SC 13G/A on Icosavax, Inc., latest Jan 10, 2024 (2 filings since Jan 10, 2023)
  • ADAMS STREET PARTNERS LLC Filed SC 13D/A on Icosavax, Inc., latest Nov 24, 2023 (3 filings since Dec 21, 2022)
  • TCG Crossover GP I, LLC Filed SC 13G on Icosavax, Inc., latest Jul 25, 2023
  • NanoDimension III, L.P. Filed SC 13G/A on Icosavax, Inc., latest Feb 14, 2023 (2 filings since Feb 10, 2022)
  • Icosavax, Inc. Seattle, Washington

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Icosavax, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$12.5M3 Dec 31, 2022$1.2M3 Dec 31, 2021+975.1%
Accumulated depreciation$943.0K3 Dec 31, 2022$83.0K3 Dec 31, 2021+1036.1%
Property and equipment, net$11.5M3 Dec 31, 2022$1.1M3 Dec 31, 2021+970.4%
Operating-lease assets (leased space)$3.2M3 Dec 31, 2022$03 Dec 31, 2021

Investments

ItemLatestA year beforeChange
Marketable securities, current$159.5M3 Dec 31, 2022$03 Dec 31, 2021

Leadership

Who has led Icosavax, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Adam K. Simpson2021–2024
2025
Board members and other officers (16)

Timeline

  1. Feb 20, 20248-K Completed an acquisition or sale; Listing notice or transfer; Change to shareholders' rights22
  2. Dec 12, 20238-K Entered a material agreement; Other events23
  3. Nov 14, 20238-K Results of operations24
  4. Aug 14, 20238-K Results of operations25
  5. Aug 8, 20238-K Regulation FD disclosure; Other events26
  6. Jun 9, 20238-K Shareholder vote27
  7. May 23, 20238-K Entered a material agreement28
  8. May 22, 20238-K Regulation FD disclosure; Other events29
  9. May 10, 20238-K Results of operations30
  10. Mar 30, 20238-K Results of operations31
  11. Dec 13, 20228-K Other events32
  12. Nov 14, 20228-K Results of operations33
  13. Jul 28, 2021New chief executive Adam K. Simpson becomes CEO7

Filings

189 filings to the SEC since October 2021: 2 annual reports, 7 quarterly reports, 25 major events, 97 insider forms, 19 large holders, 39 other. The latest 20:

  1. Mar 1, 202415-12G EDGAR
  2. Feb 21, 2024SC 13D/A EDGAR
  3. Feb 21, 2024SC 13D/A EDGAR
  4. Feb 20, 2024EFFECT EDGAR
  5. Feb 20, 20244 EDGAR
  6. Feb 20, 2024SC 14D9/A EDGAR
  7. Feb 20, 2024S-8 POS EDGAR
  8. Feb 20, 2024POS AM EDGAR
  9. Feb 20, 20248-K EDGAR
  10. Feb 20, 20244 EDGAR
  11. Feb 20, 20244 EDGAR
  12. Feb 20, 20244 EDGAR
  13. Feb 20, 20244 EDGAR
  14. Feb 20, 20244 EDGAR
  15. Feb 20, 20244 EDGAR
  16. Feb 20, 20244 EDGAR
  17. Feb 20, 20244 EDGAR
  18. Feb 20, 20244 EDGAR
  19. Feb 20, 20244 EDGAR
  20. Feb 15, 2024SC 14D9/A EDGAR

The 189 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

49 open-market trades by officers, directors and large owners since October 2021: 3 buys and 46 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Feb 1, 2024Simpson Adam K.Sale15,000$15.29$229.3KForm 4
Jan 2, 2024Simpson Adam K.Sale15,000$15.67$235.1KForm 4
Dec 21, 2023Simpson Adam K.Sale90,000$15.44$1.4MForm 4
Dec 20, 2023Simpson Adam K.Sale62,205$15.46$961.7KForm 4
Dec 20, 2023Russo Thomas JosephSale15,183$15.46$234.8KForm 4
Dec 20, 2023Kanesa-thasan NiranjanSale11,884$15.46$183.7KForm 4
Dec 20, 2023Cearley CassiaSale7,934$15.46$122.7KForm 4
Dec 13, 2023Cearley CassiaSale8,759$16.01$140.2KForm 4
Jul 31, 2023Kanesa-thasan NiranjanSale3,323$8.86$29.4KForm 4
Jul 31, 2023Simpson Adam K.Sale11,788$8.86$104.4KForm 4
Jul 31, 2023Russo Thomas JosephSale3,066$8.86$27.2KForm 4
Jul 31, 2023Cearley CassiaSale1,888$8.86$16.7KForm 4
Jul 3, 2023Holtzman DouglasChief Scientific OfficerSale16,356$8.85$144.7KForm 4
May 23, 2023Cearley CassiaSale10,000$10.00$100.0KForm 4
Apr 3, 2023Holtzman DouglasChief Scientific OfficerSale20,443$6.09$124.4KForm 4
Mar 6, 2023Cearley CassiaSale5,000$7.75$38.8KForm 4
Feb 14, 2023Holtzman DouglasChief Scientific OfficerSale3,349$10.17$34.1KForm 4
Feb 13, 2023Bekiroglu ElizabethGeneral Counsel & Corp. Sec.Sale5,922$10.69$63.3KForm 4
Feb 13, 2023Simpson Adam K.Sale7,506$10.69$80.2KForm 4
Feb 13, 2023Holtzman DouglasChief Scientific OfficerSale1,522$10.69$16.3KForm 4

All 49 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Icosavax, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARIcosavax, Inc.1
  • CIK0001786255
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address1930 Boren Ave., Suite 1000, Seattle, WA 981011
  • Phone(206) 737-00851
  • Shares outstanding50,090,341 as of Nov 8, 20236
  • Public float$184.0M as of Jun 30, 20223
  • On EDGAR sinceOct 18, 20191
  • Filings262 in all: 4 (105), 8-K (28), 3 (20), 144 (13), SC 13G (11), 10-Q (8), CORRESP (7), SC 13D/A (6)1
    All 41 form types

    UPLOAD (6), SC 13G/A (5), SC TO-T/A (5), 5 (4), SC 14D9/A (4), SC14D9C (4), EFFECT (3), SC 13D (3), 10-K (2), D (2), DEF 14A (2), DEFA14A (2), SEC STAFF LETTER (2), 15-12G (1), 25-NSE (1), 424B4 (1), 424B5 (1), 8-A12B (1), ARS (1), CERT (1), DRS (1), DRS/A (1), DRSLTR (1), POS AM (1), S-1 (1), S-1/A (1), S-1MEF (1), S-3 (1), S-8 (1), S-8 POS (1), SC 14D9 (1), SC TO-C (1), SC TO-T (1)

  • Latest filingsAnnual report (10-K) Mar 30, 2023
    Quarterly report (10-Q) Nov 14, 2023
    Proxy statement (DEF 14A) Apr 19, 2023
    Latest 8-K (8-K) Feb 20, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
    SEC EDGAROther events
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44